Press release
Melanoma Therapeutic Global Market exceeded $4 billion in 2017 and will going to surpass $10 billion by 2023 with Leading Key Companies: Bristol-Myers Squibb Company, Novartis International AG
Melanoma Therapeutic Global Market
Optimainsights.org adds New Latest Report on “Melanoma Therapeutics Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023, Focusing on Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, and Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions” reports to its database.
The Global Melanoma Therapeutic Market exceeded $4 billion in 2017 and is expected to surpass $10 billion by 2023.
Get a Sample Report PDF Here @ https://www.optimainsights.org/sample-request/19-melanoma-treatment-market-outlook-to-2022
Melanoma is a skin cancer type that involves an abnormal and uncontrollable growth of the skin cells, often developed in areas exposed to unusual higher levels of UV light or HPV infections. With an exception of melanoma, most skin cancers are not life threatening and can be effectively treated through surgery or through a therapeutic regimen that includes chemotherapy, immunotherapy and targeted agents alone or in combination.
Globally, the incidence of melanoma is gradually increasing mainly due to depleting ozone level coupled with a gradual increase in UV radiation entering the Earth’s surface. According to the World Health Organization, a 10% ozone depletion is likely to result in an additional 300,000 non-melanoma and 4,500 melanoma cases. Approximately, 287,723 people are expected to develop melanoma by the end of 2018, with Europe and North America representing over 50.1% and 24.8% of the new cases respectively. Such high proportions of incident cases highlight increased need for melanoma drugs in these regions over the forecast period.
Major market drivers include rapidly growing incidence of melanoma, environmental changes, raising awareness, increase in number of FDA fast track approvals, and increasing adoption of novel therapeutics and combination therapies are anticipated to present future growth opportunities for this market. Conversely, high cost associated with combination treatment, stringent regulations, delayed regulatory approvals and limited reimbursement, treatment side-effects are likely to restrict the market growth during the review period.
By region, North America dominates the global melanoma therapeutics market. Furthermore, Asia-pacific is expected to witness highest growth rate followed by Europe during the forecast period. In Asia-pacific, China (7, 379new melanoma cases, 2018), India (3,048new melanoma cases, 2018) and Japan (1,818new melanoma cases, 2018) are expected to be the fastest-growing melanoma therapeutics markets.
A high commercial demand of well-tolerated novel therapies along with a booming patient base in North America and Europe, has created a lucrative opportunity for drug developers in the melanoma therapeutics market. Immunotherapies with checkpoint inhibitors and BRAF/MEK drug classes are continuing to gain a strong foothold in the melanoma therapeutics market with a number of recent approvals such as avelumab (Bavencio®), ipilimumab (Yervoy®), pembrolizumab (Keytruda®), nivolumab (Opdivo®), dabrafenib (Tafinlar) and binimetinib (Mektovi). Several promising immunotherapies and combination therapies are set to reach the market with the next five years. During the forecast period, an increase in uptake of novel treatments is expected mainly due to their improved survival benefits, treatment outcomes, and minimal side effects.
Early Diners Are Offered Free Customization- Up to 20%
Get More Information on Melanoma Therapeutic Market Research Report – Forecast to 2023 @ https://www.optimainsights.org/reports/19-melanoma-treatment-market-outlook-to-2022
Table of Content
Chapter 1 Methodology and Scope
• Research Methodology
• Market Segmentation
• Research Scope & Assumptions
• Market Definitions
Chapter 2: Disease Backdrop & Patient Potential
Executive Summary
2.1 Melanoma
2.2 Etiology
2.3 Pathophysiology
2.4 Disease Burden and Economic Impact
2.5 Healthcare Expenditure (U.S., Top 5 EU and Japan)
2.6 Current Prevalence, Incidence, Risk & Co-Morbidities (U.S., Top 5 EU and Japan)
2.7 Forecast Prevalence, Incidence, Risk & Co-Morbidities (U.S., Top 5 EU and Japan)
Chapter 3: Commercial Insights
Executive Summary
3.1 Market Overview
3.2 Current MarketSize
3.4 Current Treatment Algorithm
3.5 Future Treatment Paradigm
3.6 Sales Analysis by Drug Classes
3.7 Leading Branded Drugs Dynamics
3.8 Patent Expiry analyses
3.9 Recent Large Generics/Biosimilar Drug Launches & Competition
3.10 Unmet Need Analyses
3.11 Generics Drug Pipeline
3.12 Branded Drugs Exposed to Generic Competition for 2017-2022E
3.13 Market Drivers
3.14 Market Challenges
3.15 Pricing & Reimbursement Trends
3.16 Payor Insights
3.17 Key Milestones & Events Calendar
Chapter 4: Regional Market Breakdown
Executive Summary
4.1 Melanoma Market in the U.S
4.1.1 Leading Drugs
4.1.2 Pricing & Market Access
4.1.3 New Products in Development
4.1.4 Market Players (Local & Global)
4.1.5 Regulation
4.1.6 Opportunities and Challenges
4.2 Melanoma Market in Japan
4.1.1 Leading Drugs
4.1.2 Pricing & Market Access
4.1.3 New Products in Development
4.1.4 Market Players (Local & Global)
4.1.5 Regulation
4.1.6 Opportunities and Challenges
4.3 Melanoma Market in Germany
4.1.1 Leading Drugs
4.1.2 Pricing & Market Access
4.1.3 New Products in Development
4.1.4 Market Players (Local & Global)
4.1.5 Regulation
4.1.6 Opportunities and Challenges
4.4 Melanoma Market in France
4.1.1 Leading Drugs
4.1.2 Pricing & Market Access
4.1.3 New Products in Development
4.1.4 Market Players (Local & Global)
4.1.5 Regulation
4.1.6 Opportunities and Challenges
4.5 Melanoma Market in Italy
4.1.1 Leading Drugs
4.1.2 Pricing & Market Access
4.1.3 New Products in Development
4.1.4 Market Players (Local & Global)
4.1.5 Regulation
4.1.6 Opportunities and Challenges
4.6 Melanoma Market in U.K.
4.1.1 Leading Drugs
4.1.2 Pricing & Market Access
4.1.3 New Products in Development
4.1.4 Market Players (Local & Global)
4.1.5 Regulation
4.1.6 Opportunities and Challenges
4.6 Melanoma Market in Spain
4.1.1 Leading Drugs
4.1.2 Pricing & Market Access
4.1.3 New Products in Development
4.1.4 Market Players (Local & Global)
4.1.5 Regulation
4.1.6 Opportunities and Challenges
Chapter 5: Competitive Dynamics
Executive Summary
5.1 Bristol-Myers Squibb Company
5.1.1 Company background
5.1.2 Sales focus by drug class
5.1.3 Current Product Portfolio – Major Products
5.1.4 New Product Launches
5.1.5 Sales by Region
5.1.6 Current Market Strategy
5.1.7 R&D Pipeline Analyses
5.1.8 Growth Catalyst
5.1.9 Growth Restraints
5.1.10 SWOT Analysis Framework
5.1.11 Company Outlook
5.1 Novartis International AG
5.2.1 Company Background
5.2.2 Sales Focus by Drug Class
5.2.3 Current Product Portfolio – Major Products
5.2.4 New Product Launches
5.2.5 Sales by Region
5.2.6 Key Pipeline Assets
5.2.7 Growth Catalysts
5.2.8 Growth Restraints
5.2.9 SWOT Analysis Framework
5.2.10 Company Outlook
Chapter 6: Pipeline Review
Executive Summary
6.1 Key R&D Trends
6.2 Pipeline by Stage of Development
6.3 Clinical Profiles of Key pipeline Drugs
6.4 Late-Stage Potential Game Changers
6.5 Pipeline Forecast
Chapter 7: Regulatory Environment
Executive Summary
7.1 Current Regulatory Environment
7.2 Regulatory Outlook
Chapter 8: Market Outlook
8.1 Future Market Opportunities
8.2 CXO’s Perspectives
8.3 Key Emerging companies to watch, the regulatory status & strategy
8.4 New Technologies
8.5 New Market Entrants
8.6 Expert Analyses & Commentaries
8.7 Summary Conclusions
Continued……
Ask for your specific company profile and country level customization on reports.
Purchase this Report Here @ https://www.optimainsights.org/checkout?report_id=19
RELATED REPORT YOU MIGHT BE INTERESTED
Global Head & Neck Cancer Treatment Market Outlook to 2023
Market Overview, Key in-line Products, Market Share Distribution, Competitive Dynamics, Regulatory Outlook, Pipeline Development, Growth Catalysts & Challenges, Leading Market & R&D Trends, Partnership & Deals Analyses, Global Sales forecast of in-line and pipeline products, Fast Growing Private Companies, Management Perspectives, Commentaries, Market Outlook & Summary Conclusions
https://www.optimainsights.org/reports/5-head-neck-cancer-treatment-market-outlook-to-2022
Global Lung Cancer Treatment Market Outlook to 2023
The global lung cancer drugs market was valued at $3.1bn in 2017 and is forecast to grow at a healthy 31.1% CAGR between 2017 and 2023, resulting in 2023 global sales of $20.2bn driven by targeted therapies & strong market uptake of a range of Immuno-Oncology (IO) treatments.
https://www.optimainsights.org/reports/8-lung-cancer-treatment-market-outlook-to-2022
Global Breast Cancer Treatment Market Outlook to 2023
https://www.optimainsights.org/reports/21-breast-cancer-treatment-market-outlook-to-2022
Global Ovarian Cancer Treatment Market Outlook to 2023
https://www.optimainsights.org/reports/15-ovarian-cancer-treatment-market-outlook-to-2022
Global Liver Cancer Treatment Market Outlook to 2023
https://www.optimainsights.org/reports/7-liver-cancer-treatment-market-outlook-to-2022
About Optima Insights:
Optima Insights is an innovative research and insights driven enterprise committed to offer actionable intelligence to the global life science and healthcare market players. We believe that meaningful insights and improved strategic content holds the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areasto develop targeted research solutions at compelling price point. We continuously support clients through the entire journey map to enable them take better business decisions towards attaining market leadership.
Contact:
Chucks G
Dir-Global Sales & BD
Mobile: +1 4242554365
chucksg@optimainsights.org
www.optimainsights.org
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Melanoma Therapeutic Global Market exceeded $4 billion in 2017 and will going to surpass $10 billion by 2023 with Leading Key Companies: Bristol-Myers Squibb Company, Novartis International AG here
News-ID: 1420344 • Views: …
More Releases from Optima Insights Pvt. Ltd.
Sickle Cell Anemia Therapeutics Market to Witness a Pronounce Growth During 2026
The Sickle Cell Anemia Treatment Market was valued at US$2.26 billion in the year 2018 and is estimated to reach US$6.46 billion by 2026, at a CAGR of 14.05%.
Sickle Cell Anemia is an autosomal recessive disorder caused by a mutation in the hemoglobin-β gene found on chromosome 11, due to which the red blood cells become sickle or crescent moon shaped and get stuck in small blood vessels. This can…
Market Research Report on Global Orthotic Devices Market Outlook to 2026
Orthotics can be characterized as the brace, support or splint used to align, prevent, support or to address the working of versatile body parts, for example, knee, wrist, shoulder, neck and so on. The medical field which manages the design and assembling of these devices is known as Orthotics. The orthotic devices are fundamentally used to defeat from the disabling illness, congenital condition or traumatic injury. The Overall Global Orthotic…
Neurodegenerative Disease Market Trends, Opportunities and Challenges in 2026
Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and/or death of nerve cells. This causes problems with movement (Ataxia), or mental functioning (dementia). The overall Global Neurodegenerative Disease Market is expected to grow at a significant compound CAGR rate of 6.8% from USD 32.65 billion in 2018 to USD 55.26 billion in 2026. This expansion in neurodegenerative disease is due to the ascending public awareness and…
Global Breast Cancer Treatment Market Expected to Reach $45.52 bn by 2026
The incidence of breast cancer is higher in urban areas, especially the metropolitan cities where it is now the leading female cancer and is the second most common cancer after cervix in rural and semi-urban areas. As for other cancers, late-stage presentation is also a common scenario for breast cancer. The overall Global Breast Cancer Treatment Market is expected to grow at a significant compound CAGR rate of 12.9% from…
More Releases for Melanoma
Global Melanoma Drugs Market Insights, Forecast
Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the malignant tumor. Mainly there are three general categories of melanoma as Cutaneous, mucosal and ocular. Cutaneous melanoma is melanoma of the…
Global Drugs for Melanoma Market Insights, Forecast
Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the malignant tumor. Mainly there are three general categories of melanoma as Cutaneous, mucosal and ocular. Cutaneous melanoma is melanoma of the…
Intraocular Melanoma Treatment Market Drivers
Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic…
Europe and Israel Mobile Applications for Melanoma Detection Market: Rising prev …
According to the TMR report, the Europe mobile applications for melanoma detection market could collect a larger revenue of around US$1.5 mn by the end of 2022. Even though Greece is dealing with economic volatility, it has been prognosticated to exhibit a perpetually elevating growth until the same year.
Rise in Mortality Rate and Melanoma Incidence Puts Heavy Influence on Early Diagnosis
Europe and Israel mobile applications for melanoma detection market has…
Melanoma Treatment Market – Global Industry Insights, 2025
Melanoma is a type of skin cancer that develops from the pigment cells known as melanocytes. It is caused due to high exposure to ultraviolet rays, which leads to sunburn, especially at high altitudes. Melanoma is categorized into three: cutaneous, mucosal, and ocular. Cutaneous affects the skin, mucosal affects the mucous membrane in the mouth and nasal passage, and ocular affects the eye. However, early detection of melanoma helps in…
Malignant Melanoma Drug Market Malignant Melanoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Malignant Melanoma
2. Malignant Melanoma Drug Mechanism of Action
3. Global Malignant Melanoma Market Analysis
3.1 Current Market Scenario
3.2 Global Malignant Melanoma Pipeline Overview
4. Global Malignant Melanoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. Global Malignant Melanoma Drug Market Future Prospects
6. Global Malignant Melanoma Clinical Pipeline By…
